AXE finalises terms for graphene-based quantum tech with University of Sydney


Published 16-AUG-2018 10:30 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Archer Exploration Limited (ASX:AXE) has informed the market it has finalised terms with the University of Sydney Commercial Development and Industry Partnerships (CDIP) for exclusive rights to develop and commercialise intellectual property related to carbon-based quantum computing technology.

AXE and CDIP have agreed to negotiate a definitive binding licence agreement for AXE’s exclusive international rights to develop and commercialise quantum technology IP. CDIP has agreed to deal exclusively with AXE for the execution of a proposed licence agreement for the next six months.

The key terms of the proposed licence agreement between the two parties has been finalised and remain confidential, and this process has facilitated the filing, and national phase entry, of a patent cooperation treaty (PCT) application by the University of Sydney in the geographic areas covered by a European Patent, Australia, the US, Japan, Republic of Korea and China.

Commenting on the negotiations, CEO of AXE Dr Mohammad Choucair said: “We are pleased to have finalised terms to execute the licence for the IP rights related to the carbon-based quantum computing technology with CDIP.

“When executed, the licence will provide us with patents to develop and commercially exploit the quantum computing technology across major geographic regions around the world including Europe, America and Australasia.

“Over the next six months we will focus on finalising the exclusive binding agreement and we remain very excited about the opportunity for Archer to expand in the strategic focus area of Quantum Technology,” he said.

It’s worth noting that remains a speculative play and investors should seek professional financial advice if considering this company for their portfolio.

Background on the project

The IP referred to above relates to the development of a quantum electronic device (QED) for storing and processing quantum bits (qubits) — the fundamental components of a quantum computer. In particular, the QED comprises advanced carbon material components critical for its function.

That’s where AXE comes in, as the QED requires graphene; available in the inventory of the small cap’s wholly owned subsidiary, Carbon Allotropes.

The negotiations are centred on AXE’s exclusive international rights to develop and commercialise the IP, which is described in a patent cooperation treaty (PCT) application that was filed by the University in the names of the University and École Polytechnique Fédérale de Lausanne (EPFL). The PCT was the result of quantum materials and technology research led by Dr Choucair during his previous employment at the University.

The University and EPFL finalised an inter-institutional agreement with which EPFL allows the University to take the commercialisation lead in negotiating with AXE.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free